Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Craneware Plc LSE:CRW London Ordinary Share GB00B2425G68 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  10.00 0.69% 1,450.00 67,285 16:35:07
Bid Price Offer Price High Price Low Price Open Price
1,420.00 1,460.00 1,462.50 1,440.00 1,440.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 54.64 9.52 34.78 37.3 479
Last Trade Time Trade Type Trade Size Trade Price Currency
16:59:40 O 15,270 1,425.00 GBX

Craneware (CRW) Latest News (1)

More Craneware News
Craneware Investors    Craneware Takeover Rumours

Craneware (CRW) Discussions and Chat

Craneware Forums and Chat

Date Time Title Posts
26/1/202318:57Craneware for Healthcare118
06/7/201610:59Craneware - poised to benefit from Obama healthcare reforms59
22/2/201017:31Summat called Craneware, Supposedly31

Add a New Thread

Craneware (CRW) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Craneware trades in real-time

Craneware (CRW) Top Chat Posts

Top Posts
Posted at 29/1/2023 08:20 by Craneware Daily Update
Craneware Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker CRW. The last closing price for Craneware was 1,440p.
Craneware Plc has a 4 week average price of 1,440p and a 12 week average price of 1,440p.
The 1 year high share price is 2,250p while the 1 year low share price is currently 1,340p.
There are currently 33,019,191 shares in issue and the average daily traded volume is 149,407 shares. The market capitalisation of Craneware Plc is £478,778,269.50.
Posted at 15/2/2022 18:10 by km18
...from last year....

Company overview:
Today’s company provides healthcare institutions with something crucial for the long-term prosperity of such entities – optimization of financial and operational performance. The firm argues that roughly $22 million in revenue are not captured from the average 350-bed hospital, and that is a lot even in the world of hyper expensive testing and analysis robots a modern hospital has. Craneware’s ambition is to reduce the foregone profits through its cycle experts and innovative technology which ensure transparency. They have 11  key products in their portfolio, which tackle different parts of the revenue generation cycle of each hospital. The company was founded in 1999 and currently has offices in UK and USA ad serves more than 1/3rd of the registered hospitals on US soil.
The company is growing organically, without any big acquisitions during the past 10 years. Goodwill for the period ending June 2021 was at $11.1m, or 3% which is negligible. Growth in the fundamentals is strong, with revenue CAGR of 8.68% and EPS at 4.06%. Return on capital employed is growing at 25.5% on compound basis and net gearing is negative. Return on equity is in the top quartile of the industry at 7.9% and dividends are growing at 11.6% CAGR.
Today they have released their final results for the FY 2021 (ending in June). Revenue swelled by 6% reaching $75.6m. PBT is below last year’s figures at $13.2m due to exceptional costs from the acquisition they did. As a result, EPS is down on 2020 figures to 48.1 cents. They have increased their expenditures on R&D and proposed an increase in dividends from 18.45 cents to 21.47 cents. Outlook is positive and momentum in sales is sustained in the new financial period. Management is “ confident in return to double digit organic growth”....from WealthOracleAM

https://wealthoracle.co.uk/detailed-result-full/CRW%20/186

Posted at 09/6/2021 07:07 by rimau1
The good news for private investors is that you can now buy below the placing price. High quality company and i am happy to buy back having exited last year. £21.50 and i will add more if it falls further, acquisition looks compelling given that only 33% of Sentry customers are existing CRW clients. Given high barriers to entry this is a huge cross selling opportunity.
Posted at 08/6/2021 11:10 by jombaston
They have shown scant regard for the principles of pre-emption and yet they have the nerve to put out this statement:

"Craneware consulted with a number of its major shareholders prior to the Placing and has respected the principles of pre-emption through the allocation process. The Company is pleased by the support it has received from both existing and new shareholders."

Of course, all the major shareholders knew this was coming hence the drift down in the share price. But not to save even a small amount for private investors is very disappointing especially for a 23% dilution.

I might buy some more except I haven't seen or heard the presentation that the institutions have.

Last year Diploma, a FTSE 250 member and much bigger company than CRW, made a 10% equity raise for an acquisition and gave shareholders a chance to buy through PrimaryBid. Why can't these guys do this?

I agree it would be nice for all shareholders to be treated equally but shouldn't it be mandatory?

Posted at 20/4/2021 20:28 by jonut
Rush of blood to bonce yesterday when CRW broke through my upper trend line at £25.50.Broker wouldn't give an online quote so settled on a limit at 25.50. Ask was at 26 within 10 minutes. Disinclined to increase, I left it expecting CRW to carry on up.
Close of business showed my limit accepted!

Today the ask remained at £26 but the bid dropped to 24.50. Chanced a quote, to be bid 25.60 and took it.

I should, of course be buying when the price falls through the bottom trend line but it does make you wonder what the MM's are playing at. Looking at the trades today, there are lots ~25.50 marked as buys.

Nearly made a quid anyway.

Posted at 21/1/2021 14:49 by bunz3
that video now on ggp share board , a good example for other shares
Posted at 20/1/2021 08:58 by rimau1
Good solid update. I have sold out this morning mainly because of US dollar earnings exposure and the share price has rerated over the past 6 months, high quality company and i will reinvest if it falls back during the year.
Posted at 17/11/2020 10:23 by rimau1
That was an excellent update, basically growth has returned to normalised levels so this should return to previous highs, my target price is £2900. I couldn’t resist a small top up this morning when stock was available at £1980. Quality company with an excellent outlook deserving of a premium rating
Posted at 16/11/2020 10:36 by jonut
AGM tomorrow. share price up about 25% over the last month on thinnish volumes. On dummy trades, bid is usually at the mid price.
Posted at 21/9/2020 09:34 by jonut
Full year figures today, much as expected.

https://uk.advfn.com/stock-market/london/craneware-CRW/share-news/Craneware-plc-Final-Results/83294633

Slight nudge up in revenue/ebitda. Considering the customer loss last year and Covid this year, quite a reassuring set of numbers. the forward revenue figure of 200m over the next three years is a solid foundation for further progress.

Added to my over weight position, heyho.

Posted at 04/10/2019 22:40 by melody9999
Interesting vote of confidence from Keith Ashworth Lord in the latest Buffettology monthly fact sheet.

"Craneware was the standout performer, up 40.1% as the share price recovered
from the drubbing it took in late June. In the intervening months, I had increased our share holding by over 14% having been satisfied that the company's
recent travails would be short-lived."

Well the share price has retraced since he wrote this, but he obviously has a positive view on CRW and future prospects.

Craneware share price data is direct from the London Stock Exchange
Your Recent History
LSE
CRW
Craneware
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230129 22:24:10